Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Orchestra Biomed Holdings Inc OBIO

Technology Scientific & Technical Instruments
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of... see more

Recent & Breaking News (NDAQ:OBIO)

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT(TM) for the Treatment of Hypertension in Pacemaker Patients

GlobeNewswire September 19, 2023

Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

GlobeNewswire September 6, 2023

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 10, 2023

Orchestra BioMed(TM) Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon(TM) in Patients with Coronary In-Stent Restenosis

GlobeNewswire August 8, 2023

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

GlobeNewswire June 26, 2023

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

GlobeNewswire June 7, 2023

Orchestra BioMed to Present at the Jefferies Global Healthcare Conference

GlobeNewswire June 1, 2023

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 12, 2023

Orchestra BioMed to Present at Upcoming Investor Conferences

GlobeNewswire March 7, 2023

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT(TM) and Virtue® SAB at CRT 2023

GlobeNewswire February 24, 2023

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SIMO, HPX, KWAC, HSAQ

PR Newswire July 8, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW

PR Newswire March 31, 2021

Health Sciences Acquisitions Corporation 2 Announces Closing of Upsized $160 Million Initial Public Offering, Including Full Exercise of the Underwriters' Over-Allotment Option

PR Newswire August 6, 2020

Health Sciences Acquisitions Corporation 2 Announces Pricing of Upsized $139.1 Million Initial Public Offering

PR Newswire August 4, 2020